JP2016515515A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515515A5
JP2016515515A5 JP2016502699A JP2016502699A JP2016515515A5 JP 2016515515 A5 JP2016515515 A5 JP 2016515515A5 JP 2016502699 A JP2016502699 A JP 2016502699A JP 2016502699 A JP2016502699 A JP 2016502699A JP 2016515515 A5 JP2016515515 A5 JP 2016515515A5
Authority
JP
Japan
Prior art keywords
prlr antibody
formulation
prlr
antibody formulation
polysorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515515A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/028078 external-priority patent/WO2014143909A1/en
Publication of JP2016515515A publication Critical patent/JP2016515515A/ja
Publication of JP2016515515A5 publication Critical patent/JP2016515515A5/ja
Pending legal-status Critical Current

Links

JP2016502699A 2013-03-15 2014-03-14 抗プロラクチン受容体抗体製剤 Pending JP2016515515A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799629P 2013-03-15 2013-03-15
US61/799,629 2013-03-15
PCT/US2014/028078 WO2014143909A1 (en) 2013-03-15 2014-03-14 Anti-prolactin receptor antibody formulations

Publications (2)

Publication Number Publication Date
JP2016515515A JP2016515515A (ja) 2016-05-30
JP2016515515A5 true JP2016515515A5 (https=) 2017-04-13

Family

ID=50678293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502699A Pending JP2016515515A (ja) 2013-03-15 2014-03-14 抗プロラクチン受容体抗体製剤

Country Status (10)

Country Link
US (2) US9023357B2 (https=)
EP (1) EP2968538A1 (https=)
JP (1) JP2016515515A (https=)
CN (1) CN105025925A (https=)
AR (1) AR095496A1 (https=)
CA (1) CA2906101A1 (https=)
HK (1) HK1215175A1 (https=)
TW (1) TW201513882A (https=)
UY (1) UY35460A (https=)
WO (1) WO2014143909A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361875B (es) 2012-03-14 2018-12-18 Regeneron Pharma Moléculas de unión de antígeno multiespecifícas y usos de las mismas.
EP2968538A1 (en) * 2013-03-15 2016-01-20 Bayer HealthCare LLC Anti-prolactin receptor antibody formulations
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
MX2018007520A (es) 2015-12-18 2018-08-01 Astellas Pharma Inc Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano.
IL249795B (en) 2016-02-05 2020-01-30 Grifols Worldwide Operations Ltd Intradermal administration of an immunoglobulin preparation g
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
CA3038894A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
WO2018102304A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
KR20180106974A (ko) * 2017-03-16 2018-10-01 주식회사 엘지화학 항-tnf 알파 항체의 액상 제제
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗-prlr抗體藥物軛合物(adc)及其用途
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗cd137抗体およびその使用方法
BR112020015016A2 (pt) 2018-01-26 2020-12-29 Genentech, Inc. Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
KR20250120995A (ko) 2022-11-07 2025-08-11 업스트림 바이오, 인크. 항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AR062435A1 (es) * 2006-08-18 2008-11-05 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
KR101456728B1 (ko) * 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-cd19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
JP2010512356A (ja) * 2006-12-11 2010-04-22 エフ.ホフマン−ラ ロシュ アーゲー 非経口aベータ抗体製剤
US20100189723A1 (en) * 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
PE20110302A1 (es) 2008-09-19 2011-05-21 Hoffmann La Roche Formulacion farmaceutica de un anticuerpo contra p-selectina
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
MX2011011772A (es) * 2009-05-04 2012-02-08 Abbott Biotech Ltd Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
MX2012007676A (es) 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2968538A1 (en) * 2013-03-15 2016-01-20 Bayer HealthCare LLC Anti-prolactin receptor antibody formulations

Similar Documents

Publication Publication Date Title
JP2016515515A5 (https=)
RU2015111319A (ru) Препараты антитела к рецептору анти-пролактина
RU2019100887A (ru) Композиции антитела и белка
JP2020518599A5 (https=)
JP2019504086A5 (https=)
RU2019138507A (ru) Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
RU2012131099A (ru) Препарат антитела
RU2016108652A (ru) Способы лечения спорадического миозита с тельцами включений
JP2020509031A5 (https=)
JP2015526440A5 (https=)
HRP20241526T1 (hr) Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans
JP2013518815A5 (https=)
JP2011219478A5 (https=)
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
NZ737046A (en) Anti-cgrp antibody formulation
JP2015231997A5 (https=)
RU2015123476A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
RU2017111228A (ru) Композиции антитела против IL-7R
JP2015091902A5 (https=)
JP2013543505A5 (https=)
JP2018510132A5 (https=)
JP2013500947A5 (https=)
HRP20210250T1 (hr) Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju
JP2016529255A5 (https=)
JP2019510739A5 (https=)